Tumor-associated macrophage (TAM)-related chronic inflammation and interleukin-6 (IL-6) contribute to the progression of nasopharyngeal carcinoma (NPC). In this study, we characterized TAMs and IL-6 expression in 212 biopsied NPC and 119 non-tumor nasopharyngeal epithelium (NPE) tissues by tissue array. In comparison with that in the NPE tissues, more TAM infiltrates and a higher density of IL-6 expression were detected in NPC tissues, which were associated with the poor survival of NPC patients. In contrast, little or no LPLUNC1, a regulator of inflammation, expression was detected in NPC tissues, and the levels of LPLUNC1 expression in the NPC were associated negatively with the numbers of TAMs and the levels of IL-6 expression, but positively with the survival of NPC patients. Induction of LPLUNC1 overexpression in NPC cells mitigated lipopolysaccharide (LPS)-induced IL-6, IL-8, tumor necrosis factor-a and IL-1b expression or treatment of THP-1 macrophages with LPLUNC1 inhibited spontaneous and LPS-induced IL-6 expression in vitro. IL-6-promoted NPC cell proliferation in a dose-and time-dependent manner, accompanied by increasing cyclin D1 and Bcl-2 expression and the Stat3 activation, but inhibiting Bax and p21 expression. Induction of LPLUNC1 overexpression inhibited NPC cell proliferation, induced NPC cell arrest, promoted NPC cell apoptosis even after IL-6 stimulation and inhibited the growth of implanted NPC tumors in vivo, which were associated with decreasing cyclin D1 and Bcl-2 expression and the Janus kinase 2 (JAK2)/Stat3 activation, but enhancing Bax and p21 expression. These results suggest that LPLUNC1 can inhibit inflammation and NPC growth by downregulating the Stat3 pathway.
INTRODUCTION
Inflammation has been associated with the development and progression of cancer. [1] [2] [3] [4] Infections and inflammatory responses contribute to 15-20% of mortality in patients with cancer. 5 Indeed, inflammatory cells, such as macrophages and T cells, infiltrate into tumors, and secrete many inflammatory cytokines, such as interleukin-6 (IL-6), creating a tumor microenvironment that regulates the progression and metastasis of malignant tumors. 2, 6 Inflammatory infiltrates have been suggested to be the seventh hallmark of cancer. 7 Environmental stimuli, such as bacteria, fungi and viruses continually stimulate nasopharyngeal epithelial cells that can secrete many inflammatory factors, such as IL-6, which can promote epithelial cell proliferation and transformation, particularly for Epstein-Barr virus-infected cells. 8 Furthermore, macrophage-mediated inflammation can positively regulate inflammatory cytokine production by nasopharyngeal cancer (NPC) cells and their proliferation. 9 Apparently, the interaction of inflammatory cells with NPC cells regulates the development and progression of NPC.
Macrophages are major producers of pro-inflammatory cytokines and are pivotal infiltrates within the tumor. 10 Macrophages in the tumor tissues have been referred as tumor-associated macrophages (TAMs). 11 Recently, numerous studies have shown that TAMs link tumor cells with the immune system, and may promote tumor growth and progression. 12, 13 Previous studies have suggested that the numbers of TAMs are associated with an adverse prognosis of lymphoma, 14 bladder cancer 15 and other cancers. 16 However, little is known about how the number of TAM infiltrates in tumor tissues affects the survival of patients with NPC.
IL-6 is an important regulator of immune and inflammatory responses and is also a growth factor of many types of tumor cells. 17, 18 Recent studies have revealed that the levels of serum IL-6 are elevated in NPC patients. 19, 20 Notably, many patients with NPC are infected with Epstein-Barr virus, and IL-6 through its receptor/GP130 and downstream Janus kinase (JAK)/Stat3 signaling can promote Epstein-Barr virus-positive cell proliferation. However, the effect of IL-6 on the proliferation and survival of NPC cells is not fully understood.
LPLUNC1 is a member of the bactericidal permeability increasing protein/lipid-binding protein family and can be secreted by goblet cells and minor mucosal glands of the upper respiratory tract and oral cavity. [21] [22] [23] LPLUNC1 has been shown to modulate innate immune responses to Vibrio cholerae. 24 LPLUNC1 expression is detected in mucoepidermoid carcinomas and papillary cystadenocarcinoma, 25 and our previous study has found that LPLUNC1 expression is downregulated in NPC tissues. 26 However, whether the downregulated LPLUNC1 expression is associated with the prognosis of NPC and how LPLUNC1 regulates IL-6-mediated NPC growth have not been clarified.
In this study, we measured the degrees of TAM infiltration and the levels of IL-6 and LPLUNC1 expression in NPC tissues, and evaluated the potential association of these inflammatory measures with the survival of patients with NPC. Furthermore, we determined the regulatory effects of LPLUNC1 on IL-6-mediated NPC cell proliferation and survival in vitro and on the growth of implanted NPC tumors in vivo as well as the potential mechanisms underlying the action of LPLUNC1 in regulating NPC cell proliferation.
RESULTS
The degrees of inflammation in NPC tissues are associated negatively with the survival of patients with NPC TAM-related inflammation in tumor tissues is associated with the development and progression of malignant tumors. However, there is no information on how the degrees of inflammation affect the survival of patients with NPC. Given that macrophages are major players in tumor-related inflammation, a total of 212 NPC specimens were characterized for the number of TAMs by immunohistochemistry (IHC) using anti-CD68 antibody. As shown in Figure 1a , TAMs were predominantly detected in both the stroma and tumor-cell islets in 166 out of 212 NPC specimens (78.3%). Quantitative analysis revealed that 50% of NPC samples had a high density of TAM infiltration (IHC-score 2 or 3), but only 30 out of 119 non-tumor nasopharyngeal epithelium (NPE) specimens (25.21%) had a high density of macrophage infiltration (Po0.001). Stratification of 90 patients, who had similar grades of NPC and had received similar doses of radiation therapy, indicated that 45 NPC patients with low density of TAMs (IHC-score 0 or 1) had significantly longer progression-free survival (PFS) and overall survival (OS) than those with a high density of TAMs (P ¼ 0.005, P ¼ 0.028, respectively, Figure 1b) , although the numbers of TAMs in NPC tissues were not associated with age, gender, metastasis or clinical stages.
IL-6 can be secreted by TAMs and is a growth factor of NPC. 9, 27 We further characterized the levels of IL-6 expression in 212 NPC specimens by IHC. IL-6 protein was observed in the cytoplasm of cancer cells and inflammatory infiltrates in 172 out of 212 tumor specimens (81.1%) and predominantly in inflammatory infiltrates in tumor stroma (Figure 1c Figure 1d ). More importantly, the numbers of TAMs were correlated positively with the levels of IL-6 in NPC tissues (r ¼ 0.489, Po0.001). The great numbers of TAMs and high levels of IL-6 in NPC tissues indicated severe inflammation. Therefore, the degrees of inflammation in NPC tissues were associated negatively with the lengths of PFS and OS of patients with NPC in this population.
The expression and clinical associations of LPLUNC1 in NPC tissues LPLUNC1 is highly expressed in the upper respiratory tract and has anti-inflammatory effects. To understand the role of LPLUNC1 in the development and progression of NPC, we characterized LPLUNC1 expression in 212 NPC and 119 non-tumor NPE specimens by IHC. We found that LPLUNC1 was predominantly expressed in the cytoplasma of epithelial and secreting cells in NPE tissues and a little of it in the NPC specimens (Figure 2a ). Quantitative analysis indicated that the percentages of NPE specimens with high IHC scores of anti-LPLUNC1 staining were significantly higher than that of NPC (Po0.001) and that the percentages of specimens with moderate or high IHC scores (score 2-3) of anti-LPLUNC1 staining from patients with NPC at stages I þ II were significantly higher than that of those with NPC at stages III þ V (Po0.001, Figure 2b) , suggesting that the levels of LPLUNC1 expression in NPC were associated negatively with the clinical stages of NPC in this population. Similarly, we found that a little LPLUNC1 was detected in the NPC cell lines and almost no LPLUNC1 was detected in the HNE2 cells (data not shown). The levels of LPLUNC1 expression in NPC specimens were correlated negatively with the numbers of TAMs and the levels of IL-6 expression in NPC specimens ( Figure 2c ). The levels of LPLUNC1 expression were neither associated with age and gender of patients, nor with the metastasis status and recurrence of NPC (P40.05).
To further analyze the relationship of LPLUNC1 with IL-6 expression, we characterized LPLUNC1 and IL-6 mRNA transcripts in 24 fresh NPC and 8 NPE specimens by quantitative real-time PCR (qRT-PCR). We found that the levels of LPLUNC1 mRNA transcripts in NPE specimens were significantly higher than that of NPC, whereas the levels of IL-6 mRNA transcripts in NPE were significantly lower than that in NPC (Po0.001, Figure 2d ), suggesting that the LPLUNC1 was associated negatively with the IL-6 expression in NPC samples. These data suggest that LPLUNC1 may antagonize TAM and IL-6-related inflammation and inhibit NPC progression.
LPLUNC1 inhibits lipopolysaccharide (LPS)-induced IL-6 expression in NPC cells and THP-1 macrophages LPS can induce the expression of cytokines and pro-inflammatory mediators, such as IL-6, in diverse cell types, including macrophages and nasopharyngeal epithelial cells. 8 Therefore, we investigated the effects of LPLUNC1 on LPS-induced IL-6 production in HNE2 cells and THP-1 macrophages. We transfected NPC HNE2, 5-8F and HONE1 cells with plasmid for LPLUNC1 expression, and following G418 selection, we found that LPLUNC1 was highly expressed in HNE2/LPLUNC1, 5-8F/LPLUNC1 and HONE1/LPLUNC1 cells (Figures 3a and b) . Similarly, high levels of LPLUNC1 protein were detected in the supernatants of the cultured HNE2/LPLUNC1, 5-8F/LPLUNC1 and HONE1/LPLUNC1 cells ( Figure 3c ). Interestingly, the levels of IL-6 mRNA and protein in these LPLUNC1-transfected cells were significantly lower than that in the control cells (Figure 3d ). Following stimulation with LPS (1 mg/ml) for 24 h, the levels of IL-6 were elevated in both the vector and LPLUNC1-transfected cells, whereas the levels of IL-6 in LPLUNC1-transfected cells were significantly lower than that in the controls. These data indicated that LPLUNC1 mitigated LPSstimulated IL-6 expression in NPC cells. Similarly, LPLUNC1 inhibited spontaneous and LPS-induced IL-6 production in THP-1 cells (Figure 3e ). In addition, induction of LPLUNC1 expression LPLUNC1 suppresses IL-6-induced Stat3 activation in NPC Q Liao et al mitigated LPS-stimulated tumor necrosis factor-a, IL-1b and IL-8 expression in HNE2 cells (Figure 2f) . Collectively, these data demonstrated that LPLUNC1 inhibited spontaneous and LPS-induced IL-6 expression in THP-1 cells and mitigated LPS-stimulated IL-6, IL-8, tumor necrosis factor-a and IL-1b in NPC cells in vitro.
IL-6 promotes NPC cell proliferation through activation of the Stat3 Next, we investigated the effect of IL-6 on the proliferation of NPC cells. NPC cell lines HNE2, HONE1, and 5-8F were stimulated with varying concentrations (0, 1, 10, 50 and 100 ng/ml) of IL-6 for 24 h, and the proliferation of these cells was determined by MTT assays (Figure 4a ). Clearly, IL-6-stimulated NPC cell proliferation in a dose-dependent manner. Similarly, treatment with 50 ng/ml of IL-6 for different time periods promoted NPC cell proliferation in a time-dependent manner ( Figure 4b ).
IL-6 can bind to its receptor and GP130, and activate the Stat3 and downstream signaling for cell proliferation. We found that IL-6 stimulation did not significantly change the levels of total Stat3 expression, but did significantly increase the levels of phosphor-Stat3 in HNE2, HONE1 and 5-8F (Figures 4c and d) . Therefore, our data demonstrated that IL-6-stimulated NPC cell proliferation in dose-and time-dependent manner by activating the Stat3 pathway. LPLUNC1 inhibits IL-6-enhanced NPC cell proliferation and induces NPC cell cycling arrest and apoptosis To understand the regulatory effect, we tested the impact of LPLUNC1 overexpression on the spontaneous and IL-6-enhanced NPC proliferation. We found that the proliferation of LPLUNC1-transfected NPC cells was significantly lower than that of the control cells, particularly following IL-6 stimulation (Figure 5a ), indicating that LPLUNC1 inhibited spontaneous and IL-6-enhanced NPC cell proliferation in vitro.
Further analysis of cell cycling indicated that the percentages of HNE2/LPLUNC1 cells at the G0/G1 phase were significantly higher than that of the HNE2/vector, whereas the frequency of HNE2/LPLUNC1 cells at the G2/M and S phases was significantly lower than that in the HNE2/vector cells, even after IL-6 stimulation ( Figure 5b) . A similar pattern of the percentages of different phases of 5-8F and HONE1 cells was observed (data not shown). These data clearly demonstrated that induction of LPLUNC1 overexpression induced NPC cell cycling arrest at the G0/G1 phase. Induction of cell cycling arrest is usually associated with promoting cell apoptosis. Indeed, we found that the frequency of apoptotic HNE2/LPLUNC1 cells was significantly higher than that in the HNE2/vector cells, even after IL-6 treatment ( Figure 5c ). We also detected the similar results in 5-8F and HONE1 cells (data not shown). Apparently, LPLUNC1 inhibits spontaneous and IL-6-enhanced NPC cell proliferation and induces NPC cell cycling arrest and apoptosis in vitro.
LPLUNC1 inhibits IL-6-induced Jak2/Stat3 activation in NPC cells To further understand the mechanisms underlying the action of LPLUNC1, we examined whether LPLUNC1 could attenuate IL-6-mediated JAK2/Stat3 activation in NPC cells. We found that, Correlation is significant at the 0.01 level (two-tailed).
LPLUNC1 suppresses IL-6-induced Stat3 activation in NPC Q Liao et al (Figure 6b ). In addition, significantly lower levels of Stat3 transcription activity were detected in the LPLUNC1-transfected NPC cells, as compared with that in control cells, even after stimulation (Figure 6c ). Moreover, IL-6 stimulation upregulated cyclin D1 and Bcl-2 expression in the control cells, but had little effect on the LPLUNC1-transfected NPC cells (Figures 6d and e) . Conversely, the levels of cyclin D1 and Bcl-2 expression in the LPLUNC1-transfected NPC cells were significantly lower than that in the control cells, whereas the levels of p21 and Bax in the LPLUNC1-transfected NPC cells were significantly higher than that in the control cells, even after IL-6 stimulation. Apparently, LPLUNC1-induced p21 and Bax expression, but inhibited cyclin D1 and Bcl-2 expression, contributing to the induction of cell cycling arrest and apoptosis in NPC cells in vitro.
LPLUNC1 inhibits the growth of implanted NPC tumor in vivo Finally, we tested the growth of HNE2/vector and HNE2/LPLUNC1 cells in vivo. Following inoculation of the HNE2/vector or HNE2/LPLUNC1 cells, the growth of formed tumors was monitored in Figure 7a . The growth of HNE2/LPLUNC1 tumors was much slower, and the volumes of HNE2/LPLUNC1 tumors were significantly smaller than that of the HNE2/vector tumors on day 45 after inoculation and later. The weights of HNE2/LPLUNC1 tumors were significantly less than that of the HNE2/vector tumors ( Figure 7b ). Furthermore, histological examination indicated that there were large necrotic nodules in the HNE2-LPLUNC1 tumors (Figure 7c ). IHC analyses revealed that high levels of LPLUNC1 were expressed in HNE2/LPLUNC1 tumors, accompanied by less intensity of anti-Ki67, anti-phospho-JAK2, anti-phosphor-Stat3, anti-Bcl-2 and anti-cyclin D1 staining, suggesting low levels of NPC cell proliferation and JAK2/Stat3 activity (Figure 7d ). In contrast, the intensity of anti-Bax and anti-p21 staining was higher than that in the HNE2/vector tumors, consistent with HNE2 cells in vitro. Together, our data clearly indicate that induction of LPLUNC1 overexpression inhibits the growth of HNE2 tumors in mice, which is associated with modulating the JAK2/Stat3 activation and the cell cycling-and apoptosis-related event expression in HNE2 tumors.
DISCUSSION
Inflammation has been suggested to be the seventh hallmark of cancer 7 because many types of inflammatory cells infiltrate into the tumors, which is associated with the progression of tumors. 6, [28] [29] [30] TAMs are key players, linking inflammation with cancer. 31 TAMs can secrete growth factors, inflammatory cytokines and chemokines (for example, IL-6) that support tumor survival, proliferation and invasion. 32 A high frequency of infiltrating TAMs is associated with poor prognosis of patients with different cancers. 15, [33] [34] [35] [36] In this study, we characterized the number of infiltrated TAMs and the intensity of anti-IL-6 staining in NPC and NPE tissues, and we found a high density of TAMs and anti-IL-6 staining in the NPC tissues. More importantly, the high density of TAMs was correlated with the levels of IL-6 in NPC tissues, and the density of TAMs and anti-IL-6 staining were associated with poor survival of patients with NPC. Our data extend our previous findings that TAMs and secreted cytokines support the survival of NPC cells and suggest that chronic inflammation has an important role in the progression of NPC.
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LPLUNC1 is expressed and secreted by the secretion glands and epithelium in the upper respiratory tract. 22, [37] [38] [39] Our previous studies have shown that LPLUNC1 is a tissue-specific gene in nasopharyngeal epithelia and that its expression is downregulated in NPC tissues. 26 In this study, we used a tissue array to demonstrate that the levels of LPLUNC1 expression were significantly downregulated in NPC tissues, as compared with that in non-tumor NPE tissues, and were negatively associated with the clinical stages of NPC in this population. Furthermore, we found that the levels of LPLUNC1 expression in NPC tissues were positively associated with the survival periods in patients with NPC. Given that LPLUNC1 has anti-inflammatory effects, 40 we tested the relationship between the levels of LPLUNC1 and IL-6 expression in NPC and NPE tissues. Interestingly, we found that the levels of LPLUNC1 expression were negatively associated with the levels of IL-6 expression. Evidentially, higher levels of LPLUNC1 and lower levels of IL-6 were detected in NPE tissues. In contrast, lower levels of LPLUNC1 and higher levels of IL-6 were observed in NPC tissues. In addition, induction of LPLUNC1 overexpression inhibited spontaneous and LPS-stimulated IL-6 production in NPC cells in vitro. Similarly, LPLUNC1 also attenuated spontaneous and LPS-stimulated IL-6 production in THP-1 macrophages. Apparently, LPLUNC1 is a negative regulator of chronic inflammation in NPC.
IL-6 has been demonstrated to be a crucial growth factor of some types of tumors. [41] [42] [43] We found that IL-6-stimulated NPC cell proliferation in a dose-and time-dependent manner, which was associated with IL-6 binding to its receptor-mediated downstream Stat3 activation in NPC cells. Our data were consistent with previous findings [44] [45] [46] and demonstrated that IL-6 through its receptor promoted NPC cell proliferation and NPC growth. Interestingly, we found that induction of LPLUNC1 overexpression inhibited spontaneous and IL-6-stimualted NPC cell proliferation and induced NPC cell cycling arrest and apoptosis, even after stimulation with IL-6. It is possible that LPLUNC1 may inhibit inflammation in the tumor tissues, attenuating NPC growth.
IL-6 through its IL-6 receptor/GP130 can activate the downstream Jak/Stat3 pathway, which regulates cell cycling and apoptosis. 47 Activated Stat3 has been shown to promote cell proliferation, metastasis and angiogenesis by regulating downstream genes such as Bcl-2, cyclin D1 and p21. We found high levels of Jak2/Stat3 activation in NPC cells, which was positively regulated by exogenous IL-6, consistent with previous reports. 48, 49 We found that induction of LPLUNC1 overexpression inhibited spontaneous and IL-6-promoted Stat3 activation in NPC cells, accompanied by inhibiting cyclin D1 and Bcl-2 expression and by enhancing p21 and Bax expression in NPC cells. These findings support the notion that inhibition of IL-6-induced Stat3 activation can suppress tumor cell proliferation. [50] [51] [52] Hence, LPLUNC1 may regulate cyclin D1 and p21 expression to Figure 5 . LPLUNC1 inhibits IL-6-stimulated NPC cell proliferation by inducing NPC cell cycling arrest and apoptosis. The indicated cells were stimulated with, or without, 50 ng/ml of IL-6 for 24 h, and the cell proliferation (a), cell cycling (b) and apoptosis (c) were determined by MTT and flow cytometry analysis. Data are expressed as the mean % ± s.d. of each group of cells from three separate experiments, and the spontaneous cell proliferation in the control vector was designated as 100% in proliferation assay. *Po0.05, **Po0.01 vs the controls.
LPLUNC1 suppresses IL-6-induced Stat3 activation in NPC Q Liao et al induce NPC cell cycling arrest and modulate Bcl-2 and Bax expression to promote NPC cell apoptosis. More importantly, we found that the growth of implanted LPLUNC1 overexpressing NPC tumors was significantly slower than that of wild-type NPC tumors in mice, accompanied by many necrotic nodules in the tumor tissues and lower levels of Ki67, phosphor-Stat3, phosphorJak2, Bcl-2 and cyclin D1 expression, but higher levels of p21 and Bax expression in the tumor tissues. Therefore, our data suggest that LPLUNC1 may inhibit NPC growth by inhibiting not only IL-6 production, but also IL-6-related signaling. Conceivably, modulation of LPLUNC1 expression or therapeutic treatment with LPLUNC1 may be a promising strategy for the control of NPC in the clinic.
In conclusion, our data indicated that a high density of TAMs and high levels of IL-6 expression occurred in NPC tissues and were associated with poor survival of patients with NPC in this population. Furthermore, lower levels of LPLUNC1 in NPC tissues were negatively associated with the clinical stages of NPC, but positively associated with the survival of patients with NPC. In addition, we found that LPLUNC1 inhibited spontaneous and LPS-stimulated IL-6 production in both NPC cells and macrophages, and mitigated spontaneous and IL-6-stimulated NPC cell proliferation, but induced NPC cell cycling arrest and apoptosis.
Moreover, LPLUNC1 inhibited IL-6-mediated Jak2/Stat3 activation and modulated downstream cyclin D1, p21, Bcl-2 and Bax expression, inducing NPC cell cycling arrest and apoptosis. Finally, LPLUNC1 attenuated the growth of implanted tumors in mice. Our findings may provide new insights into the regulation of LPLUNC1-related anti-inflammation on the growth of NPC and may aid in the design of new therapies for the intervention of NPC in the clinic.
MATERIALS AND METHODS

Patient samples
This study was approved by the Joint Ethics Committee of the Central South University Health Authority and performed in accordance with national guidelines. Written informed consent was obtained from individual patients who participated in the study. All human primary NPC and non-cancer NPE samples were obtained from Xiangya Hospital, Hunan, China. Individual patients with NPC were diagnosed and confirmed by pathological examination, according to the criteria established by the Chinese staging system of nasopharyngeal carcinoma in 1992 and the UICC/AJCC staging system in 2002. A total of 212 patients with NPC and 119 non-tumor patients were included in this study and their gender, age, pathological diagnosis, nodal status, metastasis and tumor-node-metastasis were recorded. These patients were treated with standard radiation Figure 6 . LPLUNC1 inhibits IL-6-induced Jak2/Stat3 activation and modulates the expression of cell cycling and apoptosis-related events in NPC cells. The indicated cells were stimulated with, or without, 50 ng/ml of IL-6 for 2 h, and the levels of JAK1/2, Stat3, cyclin D1, p21, Bcl2 and Bax expression, and JAK2 and Stat3 phosphorylation were determined by western blot, immunofluorescent assays and qRT-PCR. In addition, the LPLUNC1 suppresses IL-6-induced Stat3 activation in NPC Q Liao et al therapy, and the survival of 90 NPC patients was followed-up with a median follow-up period of 51 months (ranging from 3 to 96 months). Their demographic and clinicopathologic characteristics are summarized in Table 2 .
They were subjected to a biopsy procedure before treatment. The representative regions of individual specimens were sampled and constructed for tissue microarray, as described in our previous study. 53 
Immunohistochemistry
The expression of LPLUNC1 and IL-6 and the contents of infiltrated macrophages in individual NPC and non-tumor NPE specimens were characterized by IHC using an avidin-biotin peroxidase complex method. Briefly, individual tissue sections at 4 mM were stained with polyclonal rabbit anti-LPLUNC1 (1:500, Abnova, Taibei, Taiwan), anti-IL-6 (1:200, Boster, Wuhan, China), and anti-CD68 (Maxin, Fuzhou, China), respectively. Normal rabbit immunoglobulin G was used as negative control. The bound antibodies were detected by biotinylated goat anti-rabbit immunoglobulin G, horseradish peroxidase-conjugated avidin, and 3,3'-diaminobenzidine tetrahydrochloride. The intensity of anti-LPLUNC1 and anti-IL-6 staining was scored by 0-3, according to the standards of 0 (no staining), 1 (weak staining), 2 (medium staining) and 3 (strong staining). The percentages of CD68 þ cells in three representative high-power fields of individual samples were analyzed for macrophage infiltration and further scored as 0 (o5% of CD68 þ cells), 1 (5-25%), 2 (425-50%) and 3 (450%), as previously described.
14 Individual samples were evaluated by at least two pathologists in a blinded manner, and those samples with inconsistent scores were further discussed and decided.
Cell lines
Immortalized human NPC cell lines (5-8F, HNE2 and HONE1 cells) and THP-1 monocytes were maintained in our lab. The cells were cultivated in RPMI 1640 medium supplemented with 10% fetal calf serum in a humidified incubator at 37 1C in an atmosphere of 5% CO 2 . THP-1 monocytes were stimulated with 5 ng/ml of phorbol 12-myristate 13-acetate (Sigma, St Louis, MO, USA) for 48 h to induce THP-1 macrophage differentiation. 9, 54 Establishment of stably LPLUNC1-expressing NPC cells HNE2, 5-8F and HONE1 cells at 4 Â 10 5 /ml were cultured overnight and transfected with vector pIRESneo3 (Clontech, Mountain View, CA, USA) or pIRESneo3-LPLUNC1 (containing a full-length LPLUNC1 complementary DNA that was constructed by our laboratory) using Lipofectamine 2000, according to the manufacturer's instruction (Invitrogen, Carlsbad, CA, USA). Subsequently, the cells were treated 1 mg/ml of G418 for the selection of positive clones. The levels of LPLUNC1 expression in G418-resistant cells were characterized by qRT-PCR and western blot assays.
RNA isolation and qRT-PCR
Total RNA was extracted from NPC cells using the TRIzol extraction kit (Invitrogen) and then reversely transcribed into complementary DNA using AMV reverse transcriptase (Promega, San Luis Obispo, CA, USA). The levels of target gene mRNA transcripts were determined by qRT-PCR using specific primers and a SYBR-green-containing PCR kit (GenePharma, Shanghai, China). The sequences of primers were forward 5'-ATCGGATC-CAGCTGATGAAC-3' and reverse 5'-AGGAGGCTGGAGTAAGCACA-3' for LPLUNC1 (210 bp); forward 5'-AGGAGACTTGCCTGGTGAAA-3' and reverse 5'-CAGGGGTGGTTATTGCATCT-3' for IL-6 (180 bp); forward 5'-CGTGGC CTCTAAGATGAAGG-3' and reverse 5'-CTGGCATTTTGGAGAGGAAG-3' for cyclin D1 (185 bp); forward 5'-GGATTGTGGCCTTCTTTGAG-3' and reverse 5'-ACAGTTCCACAAAGGCATCC-3' for BCL-2 (168 bp); forward 5'-TCTGACGG CAACTTCAACTG-3' and reverse 5'-TTGAGGAGTCTCACCCAACC-3' for BAX (188 bp); forward, 5'-GCACTCAGAGGAGGCGCCATGTCA-3' and reverse 5'-GGGGCCCCGTGGGAAGGTAGAG-3' for p21 (265 bp); forward 5'-GAAGGT GAAGGTCGGAGTC-3' and reverse 5'-GAAGATGGTGATGGGATTTC-3' for glyceraldehyde 3-phosphate dehydrogenase (226 bp). The relative levels of individual gene mRNA transcripts to control glyceraldehyde 3-phosphate dehydrogenase were determined. Similarly, THP-1 cells were stimulated with, or without, 1 mg/ml of LPS in the presence or absence of exogenous LPLUNC1 for 24 h. The relative levels of IL-6 mRNA transcripts to control glyceraldehyde 3-phosphate dehydrogenase were determined by qRT-PCR.
Immunofluorescent assay
The levels of phospho-Stat3 in NPC cells were characterized by immunofluorescent assay, as described in our previous study. 8 Briefly, the NPC cells were stimulated with, or without, 50 ng/ml of recombinant human IL-6 (Cell Signaling Technology, Boston, MA, USA) for 2 h and stained with rabbit antibodies against P-Y705-Stat3 or rabbit immunoglobulin G (Cell Signaling Technology). Subsequently, the cells were stained with phycoerythrin-anti-rabbit immunoglobulin G and 4,6-diamidino-2-phenylindole, and examined under a fluorescent microscope.
Luciferase reporter assay
The transcriptional activity of Stat3 was measured by luciferase reporter gene assay. 55 Briefly, the NPC cells were transfected with control Renilla luciferase reporter plasmid mixed with a firefly luciferase reporter plasmid of pStat3-TA-luc that contained the conserved Stat3 binding site, or with blank plasmid pGL6-TA-luc (Beyotime, Jiangsu, China) at a 1:10 ratio using Lipofectamine 2000. Two days later, the cells were treated in triplicate with, or without, IL-6 (50 ng/ml) for 2 h, and the luciferase activity in different groups of cells was determined by Dual-Glo Luciferase Assay System (Promega). Firefly luciferase values were normalized against Renilla luciferases.
Western blotting NPC cell lines were treated with, or without IL-6, and the levels of targeting proteins were determined by western blot assays, as described previously 8 using primary antibodies, including anti-LPLUNC1 (Abnova, Walnut, CA, USA), anti-p-Y705-Stat3, anti-p-Jak2 (Tyr1007/1008), anti-p-Jak1 (Tyr1022/ 1023), anti-Stat3, anti-Jak2, anti-Jak1 (Cell Signaling Technology), anticyclin D1, anti-Bcl-2, anti-Bax, anti-p21 and anti-b-actin (Boster). The bound antibodies were detected by horseradish peroxidase-conjugated second antibodies and visualized using ECL ( Pierce, Rockford, IL, USA). The relative levels of individual proteins to control b-actin were analyzed by ImagJ2 software (Madison, WI, USA).
ELISA
The NPC cells were stimulated with, or without, 1 mg/ml of LPS extracted from Escherichia coli 0111:B4 (Sigma) for 24 h. Similarly, THP-1 cells were stimulated with, or without, 1 mg/ml of LPS in the presence or absence of exogenous LPLUNC1 for 24 h. The concentrations of IL-6 in the cell culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA) using IL-6 ELISA kit, according to the manufacturer's instructions (Boster). The concentrations of IL-6 were normalized to the cell numbers.
MTT assay
The effect of IL-6 or LPLUNC1 on NPC cell proliferation was measured using an MTT assay. Briefly, 4 Â 10 3 NPC cells were cultured in 96-well culture plates and stimulated in triplicate with, or without, different concentrations of IL-6 for varying periods. Subsequently, the cells were exposed to MTT (25 ml/well, 5 mg/ml, Sigma) for 4 h. The formed formazan was dissolved in 0.15 ml of dimethylsulphoxide, and the optical density values were measured at 490 nm.
Flow cytometry analysis
The distribution of different cycling phases of NPC cells was determined by flow cytometry. In brief, the NPC cells at 4 Â 10 5 per well were cultured in fetal bovine serum-free medium for 24 h and treated with, or without, 50 ng/ml of IL-6 for 24 h. The cells were harvested, fixed in 70% ethanol at 4 1C overnight, digested with 100 mg/ml of RNase A in phosphate-buffered saline, and stained with 40 mg/ml of propidium iodide for 30 min in the dark, followed by flow cytometry analysis. Additional flow cytometry was performed for analysis apoptotic cells. Briefly, the NPC cells at 4 Â 10 5 per well were treated with, or without, 50 ng/ml of IL-6 for 24 h and stained with fluorescein isothiocyanatelabeled annexin V (Invitrogen) and propidium iodide (Sigma), followed by flow cytometry analysis. Abbreviations: NPC, nasopharyngeal carcinoma; NPE, nasopharyngeal epithelium.
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